Returns to R&D on new drug introductions in the 1980s

Journal of Health Economics

Volumn 13, Issue 4, 1994, Pages 383-406

  Grabowski, Henry G ^a   Vernon, John M ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Drugs; IRR; Pharmaceuticals; R D; Returns; Risk

Indexed keywords

ACCOUNTING; ARTICLE; COST; DRUG INDUSTRY; COMMERCIAL PHENOMENA; ECONOMICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE POLICY; INCOME; INFORMATION PROCESSING; REVIEW; UNITED STATES;

NEW DRUG;

COMMERCE; COSTS AND COST ANALYSIS; DATA COLLECTION; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HEALTH POLICY; INCOME; RESEARCH SUPPORT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UNITED STATES OFFICE OF TECHNOLOGY ASSESSMENT;

EID: 0028558896     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-6296(94)90010-8     Document Type: Article

References (27)

1. A dynamic analysis of the research and experimentation credit
2. Accounting-based measures as estimates of economic rates of return: An empirical study of the U.S. pharmaceutical industry, 1976–1987
3. European policies influencing pharmaceutical innovation
4. The availability of new drugs in health maintenance organizations
5. Cost of innovation in the pharmaceutical industry
6. On the misuse of accounting rates of return to infer monopoly profits
7. An analysis of U.S. international competitiveness in pharmaceuticals
8. Industrial research and development, intangible capital stocks, and firm profit rates
9. Consumer protection regulation in ethical drugs
10. A New Look at the Returns and Risks to Pharmaceutical R&D
11. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
12. The pharmaceutical development process: Estimates of current development costs and times and the effect of changes
13. On the sensitivity of R&D to delicate tax changes: The behavior of U.S. multinationals in the 1980s
14. Prescription decisions in a managed care environment
15. A closer look at the returns and risks of pharmaceutical R&D
16. Profit Rates and Intangible Capital
17. Reference pricing and the impact of recent legislative change in Germany
18. Cost of capital estimates for investment in pharmaceutical research and development
19. The Measurement of Corporate Rates of Return: A Generalized Formation
20. Pharmaceutical idustry: Tax benefits of operating in Puerto Rico